Alok Sahay , MD

Bachelor's Degree: Sawai Man Singh Medical College Jaipur, India, 1984

Sawai Man Singh Medical College and Attached Hospitals Jaipur, India, 1985

Resident : Sawai Man Singh Medical College Jaipur, India, 1988

Medical Degree: Sawai Man Singh Medical College Jaipur, India, 1989

Residency: The Christ Hospital Cincinnati, OH, 1997

Residency: University of Cincinnati Cincinnati, OH , 2000 (Neurology)

Fellowship: Oregon Health Sciences University Portland, OR, 2001 (Movement Disorders)

American Board of Psychiatry and Neurology (Neurology) (Certification Date: 01-22-2002 ) - (Recertification Date: to 02-27-2012 )

Movement Disorders

Neurology

Parkinson's Disease

Alzheimer's Disease

Ataxia

Balance Disorders

Bell's Palsy

Cataplexy

Catatonia

Cerebellar Ataxia

Chorea

Corticobasal Degeneration (CBD)

Dementia

Dyskinesias

Dystonia

Essential Tremor (ET)

Gait Disorders

Hemifacial Spasm

Hereditary Spastic Paraplegia

Huntington's Disease

Hyperkalemic Periodic Paralysis

Hypokalemic Periodic Paralysis

Lewy Body Dementia

Lewy Body Disease

Multiple System Atrophy (MSA)

Muscle Rigidity

Muscle Spasticity

Myoclonic Seizures

Normal Pressure Hydrocephalus

Orthostatic Hypotension (Postural Hypotension)

Paraparesis

Parkinson's Hypophonia (Bowing/Atrophy)

Posterior Cortical Atrophy

Prion Disease

Psychomotor Disorders

Sensory Ataxia

Serotonin Syndrome

Spasms

Spinocerebellar Ataxia (SCA)

Spinocerebellar Degenerations

Stiff-Person Syndrome

Subacute Combined Degeneration

Tauopathies

Tay-Sachs Disease

TDP-43 Proteinopathies

Tics and Tourette Syndrome

Tourette Syndrome

Tremors

Tropical Spastic Paraparesis

Vascular Cognitive Impairment

Vascular Dementia

Wernicke Encephalopathy

Neurology

2001 -2008 Assistant Professor of Neurology, University of Cincinnati, Cincinnati, Ohio

2008 -2014 Associate Professor of Neurology, University of Cincinnati, Cincinnati, Ohio

2014 - Professor of Neurology, University of Cincinnati, Cincinnati, Ohio

1988 -1989 Medical Specialist, Bhopal Gas Relief Dept, Government of Madhya Pradesh, Bhopal, India

1989 -1990 Registrar - Neurology, Bombay Hospital & Research Center, Mumbai, India

1990 -1996 Consultant Physician, Bhopal, India

Grant: #5-25250 / R01 NS037167 Investigators:Sahay, Alok 02-02-2004 -11-30-2009 National Institute of Neurological Disorders and Stroke Parkinson Disease Collaborative Study of Genetic Linkage, PROGENI Role:PI $33,375.00 Closed Level:Federal

Grant: #089 / U01 NS 50324 Investigators:Sahay, Alok 12-01-2007 -11-30-2011 National Institute of Neurological Disorders and Stroke Effects of Coenzyme Q10 in Parkinson's Disease-Phase 3 (QE3) Role:PI $110,407.00 Closed Level:Federal

Grant: #60022880 UC Investigators:Sahay, Alok 05-01-2009 -11-29-2011 Michael J. Fox Foundation for Parkinson's Research A Pilot Phase II Double-Blind, Placebo-Controlled, Dosage Finding and Tolerability Study of Isradipine CR as a Disease Modifying Agent in Patients with Early Parkinson's Disease Role:PI $49,217.00 Closed Level:Private Non-Profit

Grant: #SRS 006658 Investigators:Sahay, Alok 10-09-2009 -10-08-2010 Michael J. Fox Foundation for Parkinson's Research Supplemental to Clinical Trial for CoQ Role:PI $2,016.00 Closed Level:Private Non-Profit

Grant: #60036745 UCC \ U01NS080818 Investigators:Sahay, Alok 08-01-2014 -03-31-2019 National Institute of Neurological Disorders and Stroke Safety, Tolerability, and Efficacy Assessment of Isradipine for Parkinson's Disease - STEADY-PD 3 Role:PI $37,375.00 Awarded Level:Federal

Peer Reviewed Publications

Beal,M. F., Oakes,D., Shoulson,I., Henchcliffe,C., Galpern,W. R., Haas,R., Juncos,J. L., Nutt,J. G., Voss,T. S., Ravina,B., Shults,C. M., Helles,K., Snively,V., Lew,M. F., Griebner,B., Watts,A., Gao,S., Pourcher,E., Bond,L., Kompoliti,K., Agarwal,P., Sia,C., Jog,M., Cole,L., Sultana,M., Kurlan,R., Richard,I., Deeley,C., Waters,C. H., Figueroa,A., Arkun,A., Brodsky,M., Ondo,W. G., Hunter,C. B., Jimenez-Shahed,J., Palao,A., Miyasaki,J. M., So,J., Tetrud,J., Reys,L., Smith,K., Singer,C., Blenke,A., Russell,D. S., Cotto,C., Friedman,J. H., Lannon,M., Zhang,L., Drasby,E., Kumar,R., Subramanian,T., Ford,D. S., Grimes,D. A., Cote,D., Conway,J., Siderowf,A. D., Evatt,M. L., Sommerfeld,B., Lieberman,A. N., Okun,M. S., Rodriguez,R. L., Merritt,S., Swartz,C. L., Martin,W. R., King,P., Stover,N., Guthrie,S., Watts,R. L., Ahmed,A., Fernandez,H. H., Winters,A., Mari,Z., Dawson,T. M., Dunlop,B., Feigin,A. S., Shannon,B., Nirenberg,M. J., Ogg,M., Ellias,S. A., Thomas,C. A., Frei,K., Bodis-Wollner,I., Glazman,S., Mayer,T., Hauser,R. A., Pahwa,R., Langhammer,A., Ranawaya,R., Derwent,L., Sethi,K. D., Farrow,B., Prakash,R., Litvan,I., Robinson,A., Sahay,A., Gartner,M., Hinson,V. K., Markind,S., Pelikan,M., Perlmutter,J. S., Hartlein,J., Molho,E., Evans,S., Adler,C. H., Duffy,A., Lind,M., Elmer,L., Davis,K., Spears,J., Wilson,S., Leehey,M. A., Hermanowicz,N., Niswonger,S., Shill,H. A., Obradov,S., Rajput,A., Cowper,M., Lessig,S., Song,D., Fontaine,D., Zadikoff,C., Williams,K., Blindauer,K. A., Bergholte,J., Propsom,C. S., Stacy,M. A., Field,J., Mihaila,D., Chilton,M., Uc,E. Y., Sieren,J., Simon,D. K., Kraics,L., Silver,A., Boyd,J. T., Hamill,R. W., Ingvoldstad,C., Young,J., Thomas,K., Kostyk,S. K., Wojcieszek,J., Pfeiffer,R. F., Panisset,M., Beland,M., Reich,S. G., Cines,M., Zappala,N., Rivest,J., Zweig,R., Lumina,L. P., Hilliard,C. L., Grill,S., Kellermann,M., Tuite,P., Rolandelli,S., Kang,U. J., Rao,J., Cook,M. M., Severt,L., Boyar,K., Investigators,Parkinson Study Group QE3 (2014. ) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit .JAMA Neurol, , 71 (5 ) ,543 -552

Stocchi,F., investigators,ADAGIO (2014. ) Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson';s disease .Eur J Neurol, , 21 (2 ) ,357 -360

Nalls,M. A., Pankratz,N., Lill,C. M., Do,C. B., Hernandez,D. G., Saad,M., DeStefano,A. L., Kara,E., Bras,J., Sharma,M., Schulte,C., Keller,M. F., Arepalli,S., Letson,C., Edsall,C., Stefansson,H., Liu,X., Pliner,H., Lee,J. H., Cheng,R., Ikram,M. A., Ioannidis,J. P., Hadjigeorgiou,G. M., Bis,J. C., Martinez,M., Perlmutter,J. S., Goate,A., Marder,K., Fiske,B., Sutherland,M., Xiromerisiou,G., Myers,R. H., Clark,L. N., Stefansson,K., Hardy,J. A., Heutink,P., Chen,H., Wood,N. W., Houlden,H., Payami,H., Brice,A., Scott,W. K., Gasser,T., Bertram,L., Eriksson,N., Foroud,T., Singleton,A. B., (IPDGC),International Parkinson's Disease Genomics Consortium, (PROGENI),Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative, 23andMe, GenePD, (NGRC),NeuroGenetics Research Consortium, (HIHG),Hussman Institute of Human Genomics, Investigator,Ashkenazi Jewish Dataset, (CHARGE),Cohorts for Health and Aging Research in Genetic Epidemiology, (NABEC),North American Brain Expression Consortium, (UKBEC),United Kingdom Brain Expression Consortium, Consortium,Greek Parkinson's Disease, Group,Alzheimer Genetic Analysis (2014. ) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson';s disease .Nat Genet, , 46 (9 ) ,989 -993

Marek,K., Seibyl,J., Eberly,S., Oakes,D., Shoulson,I., Lang,A. E., Hyson,C., Jennings,D., Investigators,Parkinson Study Group PRECEPT (2014. ) Longitudinal follow-up of SWEDD subjects in the PRECEPT Study .Neurology, , 82 (20 ) ,1791 -1797

Hauser,R. A., Silver,D., Choudhry,A., Eyal,E., Isaacson,S., investigators,ANDANTE study (2014. ) Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson';s disease .Mov Disord, , 29 (8 ) ,1028 -1034

Evidente,V. G., Fernandez,H. H., LeDoux,M. S., Brashear,A., Grafe,S., Hanschmann,A., Comella,C. L. (2013. ) A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia .J Neural Transm, , 120 (12 ) ,1699 -1707

Fernandez,H. H., Pappert,E. J., Comella,C. L., Evidente,V. G., Truong,D. D., Verma,A., Jankovic,J. (2013. ) Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia .Tremor Other Hyperkinet Mov (N Y), , 3 ,

Group,Parkinson Study (2013. ) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson';s disease (STEADY-PD) .Mov Disord, , 28 (13 ) ,1823 -1831

Truong,D. D., Gollomp,S. M., Jankovic,J., LeWitt,P. A., Marx,M., Hanschmann,A., Fernandez,H. H., Group,Xeomin US Blepharospasm Study (2013. ) Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm .J Neural Transm, , 120 (9 ) ,1345 -1353

Pankratz,N., Beecham,G. W., DeStefano,A. L., Dawson,T. M., Doheny,K. F., Factor,S. A., Hamza,T. H., Hung,A. Y., Hyman,B. T., Ivinson,A. J., Krainc,D., Latourelle,J. C., Clark,L. N., Marder,K., Martin,E. R., Mayeux,R., Ross,O. A., Scherzer,C. R., Simon,D. K., Tanner,C., Vance,J. M., Wszolek,Z. K., Zabetian,C. P., Myers,R. H., Payami,H., Scott,W. K., Foroud,T., Consortium,PD GWAS (2012. ) Meta-analysis of Parkinson';s disease: identification of a novel locus, RIT2 .Ann Neurol, , 71 (3 ) ,370 -384

Espay,Alberto J., Vaughan,Jennifer E., Shukla,Rakesh, Gartner,Maureen, Sahay,Alok, Revilla,Fredy J., Duker,Andrew P. (2011. ) Botulinum Toxin Type A for Levodopa-Induced Cervical Dyskinesias in Parkinson';s Disease: Unfavorable Risk-Benefit Ratio .Movement Disorders, , 26 (5 ) ,913 -914

Pankratz,N., Dumitriu,A., Hetrick,K. N., Sun,M., Latourelle,J. C., Wilk,J. B., Halter,C., Doheny,K. F., Gusella,J. F., Nichols,W. C., Myers,R. H., Foroud,T., DeStefano,A. L., PSG-PROGENI and GenePD Investigators,C.ordinators and Molecular Genetic Laboratories (2011. ) Copy number variation in familial Parkinson disease .PLoS One, , 6 (8 ) ,e20988

Espay,Alberto J., Giuffrida,Joe P., Chen,Robert, Payne,Megan, Mazzella,Filomena, Dunn,Emily, Vaughan,Jennifer E., Duker,Andrew P., Sahay,Alok, Kim,Sang Jin, Revilla,Fredy J., Heldman,Dustin A. (2011. ) Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson';s disease .Movement Disorders, , 26 (14 ) ,2504 -2508

Comella,C. L., Jankovic,J., Truong,D. D., Hanschmann,A., Grafe,S., Group,U. S. XEOMIN Cervical Dystonia Study (2011. ) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia .J Neurol Sci, , 308 (1-2 ) ,103 -109

Espay,A. J., Dwivedi,A. K., Payne,M., Gaines,L., Vaughan,J. E., Maddux,B. N., Slevin,J. T., Gartner,M., Sahay,A., Revilla,F. J., Duker,A. P., Shukla,R. (2011. ) Methylphenidate for gait impairment in Parkinson disease A randomized clinical trial .Neurology, , 76 (14 ) ,1256 -1262

Marras,Connie, McDermott,Michael P., Marek,Ken, Rochon,Paula, Naglie,Gary, Tanner,Caroline M., Rudolph,Alice, Shoulson,Ira, Lang,Anthony E., Parkinson Study Grp,Datatop Invest, Parkinson Study Grp,Precept Invest (2011. ) Predictors of Time to Requiring Dopaminergic Treatment in 2 Parkinson';s Disease Cohorts .Movement Disorders, , 26 (4 ) ,608 -613

Schwarzschild,Michael A., Marek,Kenneth, Eberly,Shirley, Oakes,David, Shoulson,Ira, Jennings,Danna, Seibyl,John, Ascherio,Alberto, Parkinson Study Grp,Precept (2011. ) Serum Urate and Probability of Dopaminergic Deficit in Early "Parkinson';s Disease" .Movement Disorders, , 26 (10 ) ,1864 -1868

Heldman,Dustin A., Giuffrida,Joseph P., Chen,Robert, Payne,Megan, Mazzella,Filomena, Duker,Andrew P., Sahay,Alok, Kim,Sang Jin, Revilla,Fredy J., Espay,Alberto J. (2011. ) The Modified Bradykinesia Rating Scale for Parkinson';s Disease: Reliability and Comparison with Kinematic Measures .Movement Disorders, , 26 (10 ) ,1859 -1863

Kieburtz,Karl, Parkinson Study Grp Prami,B. I. D. (2011. ) Twice-Daily, Low-Dose Pramipexole in Early Parkinson';s Disease: A Randomized, Placebo-Controlled Trial .Movement Disorders, , 26 (1 ) ,37 -44

Schwid,Steven R., Bausch,Janice, Oakes,David, Schuchter,Lynn, Tanner,Caroline, Forrest,Misser, Lang,Anthony E., Shoulson,Ira, Investigators,Psg Precept (2010. ) Cancer Incidence in a Trial of an Antiapoptotic Agent for Parkinson';s Disease .Movement Disorders, , 25 (12 ) ,1801 -1808

Simon,David K., Pankratz,Nathan, Kissell,Diane K., Pauciulo,Michael W., Halter,Cheryl A., Rudolph,Alice, Pfeiffer,Ronald F., Nichols,William C., Foroud,Tatiana, Parkinson Study Grp,Progeni Invest (2010. ) Maternal inheritance and mitochondrial DNA variants in familial Parkinson';s disease .Bmc Medical Genetics, , 11 ,

Watts,R. L., Lyons,K. E., Pahwa,R., Sethi,K., Stern,M., Hauser,R. A., Olanow,W., Gray,A. M., Adams,B., Earl,N. L., Investigators,228 Study (2010. ) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson';s disease .Mov Disord, , 25 (7 ) ,858 -866

Marras,Connie, Lang,Anthony E., Eberly,Shirley W., Oakes,David, Fahn,Stanley, Schwid,Steven R., Hyson,Christopher, Shoulson,Ira, Parkinson Study Grp,Datatop Precep (2009. ) A Comparison of Treatment Thresholds in Two Large Parkinson';s Disease Clinical Trial Cohorts .Movement Disorders, , 24 (16 ) ,2370 -2378

Olanow,C. W., Rascol,O., Hauser,R., Feigin,P. D., Jankovic,J., Lang,A., Langston,W., Melamed,E., Poewe,W., Stocchi,F., Tolosa,E., Investigators,ADAGIO Study (2009. ) A double-blind, delayed-start trial of rasagiline in Parkinson';s disease .N Engl J Med, , 361 (13 ) ,1268 -1278

Pankratz,Nathan, Nichols,William C., Elsaesser,Veronika E., Pauciulo,Michael W., Marek,Diane K., Halter,Cheryl A., Wojcieszek,Joanne, Rudolph,Alice, Pfeiffer,Ronald F., Foroud,Tatiana, Parkinson Study Grp,Progeni Invest (2009. ) Alpha-Synuclein and Familial Parkinson';s Disease .Movement Disorders, , 24 (8 ) ,1125 -1131

Latourelle,J. C., Pankratz,N., Dumitriu,A., Wilk,J. B., Goldwurm,S., Pezzoli,G., Mariani,C. B., DeStefano,A. L., Halter,C., Gusella,J. F., Nichols,W. C., Myers,R. H., Foroud,T., PROGENI Investigators,C.ordinators and Molecular Genetic Laboratories, GenePD Investigators,C.ordinators and Molecular Genetic Laboratories (2009. ) Genomewide association study for onset age in Parkinson disease .BMC Med Genet, , 10 ,98

Pankratz,N., Wilk,J. B., Latourelle,J. C., DeStefano,A. L., Halter,C., Pugh,E. W., Doheny,K. F., Gusella,J. F., Nichols,W. C., Foroud,T., Myers,R. H., PSG-PROGENI and GenePD Investigators,C.ordinators and Molecular Genetic Laboratories (2009. ) Genomewide association study for susceptibility genes contributing to familial Parkinson disease .Hum Genet, , 124 (6 ) ,593 -605

Nichols,W. C., Pankratz,N., Marek,D. K., Pauciulo,M. W., Elsaesser,V. E., Halter,C. A., Rudolph,A., Wojcieszek,J., Pfeiffer,R. F., Foroud,T., Parkinson Study Grp,Progeni (2009. ) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset .Neurology, , 72 (4 ) ,310 -316

Pankratz,N., Kissell,D. K., Pauciulo,M. W., Halter,C. A., Rudolph,A., Pfeiffer,R. F., Marder,K. S., Foroud,T., Nichols,W. C., Parkinson Study Grp,Progeni Invest (2009. ) Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations .Neurology, , 73 (4 ) ,279 -286

Nichols,W. C., Kissell,D. K., Pankratz,N., Pauciulo,M. W., Elsaesser,V. E., Clark,K. A., Halter,C. A., Rudolph,A., Wojcieszek,J., Pfeiffer,R. F., Foroud,T., Parkinson Study Grp,Progeni Invest (2009. ) Variation in GIGYF2 is not associated with Parkinson disease .Neurology, , 72 (22 ) ,1886 -1892

Pankratz,N., Marder,K. S., Halter,C. A., Rudolph,A., Shults,C. W., Nichols,W. C., Foroud,T., Investigators,Parkinson's Study Group-PROGENI (2008. ) Clinical correlates of depressive symptoms in familial Parkinson';s disease .Mov Disord, , 23 (15 ) ,2216 -2223

Schwarzschild,M. A., Schwid,S. R., Marek,K., Watts,A., Lang,A. E., Oakes,D., Shoulson,I., Ascherio,A., Hyson,C., Gorbold,E., Rudolph,A., Kieburtz,K., Fahn,S., Gauger,L., Goetz,C., Seibyl,J., Forrest,M., Ondrasik,J., Investigators,Parkinson Study Group PRECEPT (2008. ) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease .Arch Neurol, , 65 (6 ) ,716 -723

Nichols,W. C., Elsaesser,V. E., Pankratz,N., Pauciulo,M. W., Marek,D. K., Halter,C. A., Rudolph,A., Shults,C. W., Foroud,T., Parkinson Study Grp,Progeni Invest (2007. ) LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 .Neurology, , 69 (18 ) ,1737 -1744

Investigators,Parkinson Study Group PRECEPT (2007. ) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease .Neurology, , 69 (15 ) ,1480 -1490

Nichols,William C., Marek,Diane K., Pauciulo,Michael W., Pankratz,Nathan, Halter,Cheryl A., Rudolph,Alice, Shults,Clifford W., Wojcieszek,Joanne, Foroud,Tatiana, Investigators,Progeni (2007. ) R1514Q substitution in Lrrk2 is not a pathogenic Parkinson';s disease mutation .Movement Disorders, , 22 (2 ) ,254 -257

Goetz,C. G., Damier,P., Hicking,C., Laska,E., Müller,T., Olanow,C. W., Rascol,O., Russ,H. (2007. ) Sarizotan as a treatment for dyskinesias in Parkinson';s disease: a double-blind placebo-controlled trial .Mov Disord, , 22 (2 ) ,179 -186

Blindauer,K., Shoulson,I., Oakes,D., Kieburtz,K., Schwid,S., Fahn,S., Stern,M., Goetz,C., Nutt,J., Plumb,S., Shinaman,A., Truong,D., Pahwa,R., Factor,S., Evans,S., Wojcieszek,J., Belden,J., Adler,C., Lind,M., Panisset,M., Hall,J., Suchowersky,O., Derwent,L., Di Rocco,A., Boyar,K., Ondo,W., Hunter,C., Colcher,A., Aminoff,M., Dowling,G., Outlaw,H., Dalvi,A., Sahay,A., Schwieterman,D., Elmer,L., Weiner,W., Cines,M., Dignon,C., Frucht,S., Benabou,R., Rajput,A., Ewanishin,M., Jennings,D., Stavris,K., Martin,W., McInnes,G., King,P., Feigin,A., Shannon,B., Gordon,M. F., Atchison,P., Mendis,T., Mendis,N., Reich,S., Dunlop,B., Petzinger,G., Armstrong,C., Welsh,M., Pfeiffer,R., Pfeiffer,B., Tuite,P., Calabrese,V., Roberge,P., Jog,M., Horn,C., Blackstone,C., Growdon,J., Tennis,M., Hauser,R., Gauger,L., Stacy,M., Williamson,K., O'Brien,C., Seeberger,L., Judd,D., Demarcaida,A., Belber,S., Perlmutter,J., McGee-Minnich,L., Ramos,C. S., Berrios,L., Bertoni,J., Peterson,C., Marshall,F., Deeley,C., Verhagen,L., Jaglin,J., Koller,W., Lyons,K., Singer,C., Blenke,A., Mark,M., Caputo,D., Tarsy,D., Scollins,L., Thomas,C. A., Rivest,J., Soucy,D., Bausch,J., Brocht,A., Daigneault,S., Eberly,S., Irvine,C., Lindsay,P., Weaver,C., Tariot,P., Cox,C., Leventhal,C., Goren,S., Sayag,N., Scolnik,M., Levy,R., Eyal,E., Salzman,P., Pagano,M., Parkinson Study,Grp (2006. ) A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations .Archives of Neurology, , 63 (2 ) ,210 -216

Schmit,J. M., Riley,M. A., Dalvi,A., Sahay,A., Shear,P. K., Shockley,K. D., Pun,R. Y. (2006. ) Deterministic center of pressure patterns characterize postural instability in Parkinson';s disease .Exp Brain Res, , 168 (3 ) ,357 -367

Strong,J. A., Dalvi,A., Revilla,F. J., Sahay,A., Samaha,F. J., Welge,J. A., Gong,J., Gartner,M., Yue,X., Yu,L. (2006. ) Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson';s disease .Mov Disord, , 21 (5 ) ,654 -659

Pankratz,Nathan, Pauciulo,Michael W., Elsaesser,Veronika E., Marek,Diane K., Halter,Cheryl A., Wojcieszek,Joanne, Rudolph,Alice, Shults,Clifford W., Foroud,Tatiana, Nichols,William C., Parkinson Study Grp,Progeni Invest (2006. ) Mutations in DJ-1 are rare in familial Parkinson disease .Neuroscience letters, , 408 (3 ) ,209 -213

Pankratz,N., Pauciulo,M. W., Elsaesser,V. E., Marek,D. K., Halter,C. A., Rudolph,A., Shults,C. W., Foroud,T., Nichols,W. C., Investigators,Parkinson Study Group-PROGENI (2006. ) Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson';s disease .Mov Disord, , 21 (12 ) ,2257 -2260

Yang,T., Lu,A. G., Ran,R. Q., Aronow,B. J., Schorry,E. K., Hopkin,R. J., Gilbert,D. L., Glauser,T. A., Hershey,A. D., Richtand,N. W., Privitera,M., Dalvi,A., Sahay,A., Szaflarski,J. P., Ficker,D. M., Ratner,N., Sharp,F. R. (2004. ) Human blood genomics: distinct profiles for gender, age and neurofibromatosis type 1 .Molecular Brain Research, , 132 (2 ) ,155 -167

Electronic Journal

Alberto J Espay, Alok Sahay and Fredy J. Revilla (2006. ) Palilalia in Parkinsonism: localizable to the globus pallidus? .J Neurol Neurosugery Psychiatry eLetters for Owens and Okum , 75 (9 ) ,

Shoulson I, Lang A E, Bozyczko-Coyne D on behalf of Parkinson Study Group – PRECEPT Investigators (2008. ) Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease .Neurology , 71 (6 ) ,

1998 -To Present: American Medical Association,

1998 -To Present: American Academy of Neurology,

2000 -To Present: Movement Disorder Society,

2002 -To Present: Parkinson Study Group,

Academic - One Stetson Square
260 Stetson Street
Cincinnati  Ohio, 45219-0525
Phone: 513-558-4050
Fax: 513-558-4305
alok.sahay@uc.edu

Academic - WCH
7700 University Drive
West Chester  Ohio, 45069
Phone: 513-475-8730
alok.sahay@uc.edu

Academic - UCGNI
3113 Bellevue Avenue
Cincinnati  Ohio, 45219
Phone: 513-475-8730
Fax: 513-475-8033
alok.sahay@uc.edu